Tom Gonda

Honorary Professor Tom Gonda is affiliated with the School of Pharmacy and Pharmaceutical Sciences at the University of Queensland. His research spans molecular oncology with a focus on transcriptional regulation, particularly the MYB oncogene, and its role in leukemia and other cancers.

Professor Gonda's research interests center on the molecular mechanisms of cancer development, with special emphasis on the MYB transcription factor and its role in leukemogenesis. His work has significantly advanced understanding of how MYB dysregulation contributes to acute myeloid leukemia (AML) and other malignancies. His laboratory investigates transcriptional regulation, DNA damage response pathways, and the molecular basis of hematopoietic differentiation. His research has important implications for developing targeted therapies for leukemia and other cancers.

Analysis of Professor Gonda's publication record from 2016-2023 reveals a consistent focus on MYB-related oncogenesis across multiple cancer types, particularly acute myeloid leukemia. His work demonstrates how MYB interacts with other transcription factors (like C/EBPβ and p300) and chromatin regulators to drive leukemogenesis. Recent publications highlight the role of mitochondrial dysfunction and DNA repair defects in AML, suggesting novel therapeutic vulnerabilities. His research also extends to breast cancer, where MYB regulates DNA damage response pathways in estrogen receptor-positive disease.

Professor Gonda has mentored numerous researchers throughout his career, with collaborations spanning multiple institutions and disciplines. His laboratory has contributed significantly to understanding the molecular basis of hematopoietic malignancies through extensive publication in high-impact journals.

His research is conducted within the School of Pharmacy and Pharmaceutical Sciences at the University of Queensland, where he maintains an active laboratory investigating transcriptional regulation in cancer. His work bridges basic molecular biology with translational applications for cancer therapy.